WO2020168317A3 - Cellules souches donnatrices universelles et méthodes associées - Google Patents
Cellules souches donnatrices universelles et méthodes associées Download PDFInfo
- Publication number
- WO2020168317A3 WO2020168317A3 PCT/US2020/018467 US2020018467W WO2020168317A3 WO 2020168317 A3 WO2020168317 A3 WO 2020168317A3 US 2020018467 W US2020018467 W US 2020018467W WO 2020168317 A3 WO2020168317 A3 WO 2020168317A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- stem cells
- universal donor
- donor stem
- related methods
- disclosed
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1114—T cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Abstract
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202080021860.7A CN113906048A (zh) | 2019-02-15 | 2020-02-16 | 通用供体干细胞和相关方法 |
EA202192264A EA202192264A1 (ru) | 2019-10-08 | 2020-02-16 | Универсальные донорские стволовые клетки и соответствующие способы |
BR112021016178A BR112021016178A2 (pt) | 2019-02-15 | 2020-02-16 | Células-tronco doadoras universais e métodos relacionados |
JP2021547755A JP2022526218A (ja) | 2019-02-15 | 2020-02-16 | 汎用ドナー幹細胞及び関連する方法 |
EP20755906.3A EP3924375A4 (fr) | 2019-02-15 | 2020-02-16 | Cellules souches donnatrices universelles et méthodes associées |
MX2021009842A MX2021009842A (es) | 2019-02-15 | 2020-02-16 | Células madre de donantes universales y métodos relacionados. |
CA3130398A CA3130398A1 (fr) | 2019-02-15 | 2020-02-16 | Cellules souches donnatrices universelles et methodes associees |
KR1020217029445A KR20210128440A (ko) | 2019-02-15 | 2020-02-16 | 범용 공여자 줄기 세포 및 관련 방법 |
AU2020223192A AU2020223192A1 (en) | 2019-02-15 | 2020-02-16 | Universal donor stem cells and related methods |
SG11202108891QA SG11202108891QA (en) | 2019-02-15 | 2020-02-16 | Universal donor stem cells and related methods |
IL285619A IL285619A (en) | 2019-02-15 | 2021-08-15 | Universal donor stem cells and related methods |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201916277913A | 2019-02-15 | 2019-02-15 | |
US16/277,913 | 2019-02-15 | ||
US201916596697A | 2019-10-08 | 2019-10-08 | |
US16/596,697 | 2019-10-08 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2020168317A2 WO2020168317A2 (fr) | 2020-08-20 |
WO2020168317A3 true WO2020168317A3 (fr) | 2020-10-29 |
WO2020168317A8 WO2020168317A8 (fr) | 2021-02-25 |
Family
ID=72045137
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2020/018467 WO2020168317A2 (fr) | 2019-02-15 | 2020-02-16 | Cellules souches donnatrices universelles et méthodes associées |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP3924375A4 (fr) |
JP (1) | JP2022526218A (fr) |
KR (1) | KR20210128440A (fr) |
CN (1) | CN113906048A (fr) |
AU (1) | AU2020223192A1 (fr) |
BR (1) | BR112021016178A2 (fr) |
CA (1) | CA3130398A1 (fr) |
IL (1) | IL285619A (fr) |
MX (1) | MX2021009842A (fr) |
SG (1) | SG11202108891QA (fr) |
WO (1) | WO2020168317A2 (fr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4149525A1 (fr) * | 2020-05-15 | 2023-03-22 | Rxcell Inc. | Cellules hypo-immunogènes et leurs utilisations dans des réponses immunitaires |
CN114457021A (zh) * | 2020-10-30 | 2022-05-10 | 未来智人再生医学研究院(广州)有限公司 | 一种表达cd47抗体的多能干细胞及其衍生物与应用 |
CN114525256A (zh) * | 2020-10-30 | 2022-05-24 | 未来智人再生医学研究院(广州)有限公司 | 一种表达Siglec-15阻断物的多能干细胞或其衍生物及应用 |
US11459372B2 (en) | 2020-11-30 | 2022-10-04 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
AU2021396403A1 (en) * | 2020-12-11 | 2023-06-29 | Intellia Therapeutics, Inc. | Compositions and methods for reducing mhc class ii in a cell |
WO2022140587A1 (fr) * | 2020-12-23 | 2022-06-30 | Intellia Therapeutics, Inc. | Compositions et procédés pour modifier génétiquement le ciita dans une cellule |
CA3200509A1 (fr) | 2020-12-31 | 2022-07-07 | Sonja SCHREPFER | Methodes et compositions pour moduler une activite de car-t |
AU2022283291A1 (en) | 2021-05-27 | 2023-11-02 | Sana Biotechnology, Inc. | Hypoimmunogenic cells comprising engineered hla-e or hla-g |
CA3227613A1 (fr) | 2021-08-11 | 2023-02-16 | William Dowdle | Systemes inductibles pour modifier l'expression genique dans des cellules hypoimmunogenes |
WO2023122337A1 (fr) | 2021-12-23 | 2023-06-29 | Sana Biotechnology, Inc. | Lymphocytes t à récepteur antigénique chimérique (car) pour le traitement d'une maladie auto-immune et méthodes associées |
WO2023154578A1 (fr) | 2022-02-14 | 2023-08-17 | Sana Biotechnology, Inc. | Méthodes de traitement de patients présentant une thérapie préalable ayant échoué avec des cellules hypoimmunogènes |
WO2023191063A1 (fr) * | 2022-04-01 | 2023-10-05 | 株式会社Logomix | Cellule appropriée pour l'ingénierie génique, l'ingénierie cellulaire et la médecine cellulaire, et son procédé de production |
WO2024003349A1 (fr) | 2022-07-01 | 2024-01-04 | Novo Nordisk A/S | Amélioration de la différenciation neuronale de cellules progénitrices neurales du mésencéphale ventral |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016183041A2 (fr) * | 2015-05-08 | 2016-11-17 | President And Fellows Of Harvard College | Cellules souches de donneur universel et procédés associés |
WO2018132783A1 (fr) * | 2017-01-13 | 2018-07-19 | The Regents Of The University Of California | Cellules pluripotentes immunologiquement modifiées |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108368520B (zh) * | 2015-11-04 | 2023-01-17 | 菲特治疗公司 | 多能细胞的基因组工程改造 |
-
2020
- 2020-02-16 JP JP2021547755A patent/JP2022526218A/ja active Pending
- 2020-02-16 WO PCT/US2020/018467 patent/WO2020168317A2/fr unknown
- 2020-02-16 EP EP20755906.3A patent/EP3924375A4/fr not_active Withdrawn
- 2020-02-16 AU AU2020223192A patent/AU2020223192A1/en not_active Abandoned
- 2020-02-16 BR BR112021016178A patent/BR112021016178A2/pt unknown
- 2020-02-16 SG SG11202108891QA patent/SG11202108891QA/en unknown
- 2020-02-16 CA CA3130398A patent/CA3130398A1/fr active Pending
- 2020-02-16 MX MX2021009842A patent/MX2021009842A/es unknown
- 2020-02-16 KR KR1020217029445A patent/KR20210128440A/ko unknown
- 2020-02-16 CN CN202080021860.7A patent/CN113906048A/zh active Pending
-
2021
- 2021-08-15 IL IL285619A patent/IL285619A/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016183041A2 (fr) * | 2015-05-08 | 2016-11-17 | President And Fellows Of Harvard College | Cellules souches de donneur universel et procédés associés |
WO2018132783A1 (fr) * | 2017-01-13 | 2018-07-19 | The Regents Of The University Of California | Cellules pluripotentes immunologiquement modifiées |
Non-Patent Citations (2)
Title |
---|
HARRER, J: "Generation of stem cell -derived hypoimmunogenic beta cells that circumvent immune detection", MASTER'S THESIS . DEGREE PROGRAM TISSUE ENGINEERING AND REGENERATIVE MEDICINE UNIVERSITY OF APPLIED SCIENCES, September 2018 (2018-09-01), Vienna, XP055640701, Retrieved from the Internet <URL:https://static1.squarespace.com/static/559921a3e4b02c1d7480f8f4/t/5c790ded24a69426265feb35/1551437298166/Harrer+Jacqueline_852pdf> * |
MATTAPALLY, S ET AL.: "Human Leukocyte Antigen Class I and II Knockout Human Induced Pluripotent Stem Cell -Derived Cells: Universal Donor for Cell Therapy", JOURNAL OF THE AMERICAN HEART ASSOCIATION, vol. 7, no. 23, 29 November 2018 (2018-11-29), pages e010239, XP055755732, DOI: 10.1161/JAHA.118.010239 * |
Also Published As
Publication number | Publication date |
---|---|
IL285619A (en) | 2021-09-30 |
KR20210128440A (ko) | 2021-10-26 |
JP2022526218A (ja) | 2022-05-24 |
SG11202108891QA (en) | 2021-09-29 |
CA3130398A1 (fr) | 2020-08-20 |
EP3924375A2 (fr) | 2021-12-22 |
AU2020223192A1 (en) | 2021-09-09 |
CN113906048A (zh) | 2022-01-07 |
WO2020168317A8 (fr) | 2021-02-25 |
WO2020168317A2 (fr) | 2020-08-20 |
MX2021009842A (es) | 2021-12-10 |
EP3924375A4 (fr) | 2023-03-22 |
BR112021016178A2 (pt) | 2021-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020168317A3 (fr) | Cellules souches donnatrices universelles et méthodes associées | |
WO2016183041A3 (fr) | Cellules souches de donneur universel et procédés associés | |
WO2019014351A3 (fr) | Cellules de donneur universel et procédés associés | |
PH12021550476A1 (en) | Universal donor cells | |
Peters et al. | Stem-cell transplantation in children with acute lymphoblastic leukemia: A prospective international multicenter trial comparing sibling donors with matched unrelated donors-The ALL-SCT-BFM-2003 trial. | |
WO2020018615A3 (fr) | Cellules différenciées de cellules pluripotentes obtenues par immuno-ingénierie | |
WO2019178005A3 (fr) | Procédés de traitement de maladies associées au hpv | |
WO2018098365A3 (fr) | Compositions et méthodes de reprogrammation de tcr au moyen de protéines de fusion | |
WO2017160717A3 (fr) | Méthode de traitement de maladies à l'aide de modulateurs de kinases | |
MX2022002783A (es) | Celulas donantes universales. | |
MX2022002663A (es) | Celulas donantes universales. | |
TWD203424S (zh) | 汽車車體 | |
WO2007140472A3 (fr) | Expression de cd127 inversement proportionnelle à foxp3 et fonction suppressive des tregs cd4+ | |
WO2019099921A3 (fr) | Formulations de protéines de fusion vegfr-fc | |
TWD203041S (zh) | 智慧家教機器人 | |
WO2020099352A3 (fr) | Peptides immunogènes dotés de nouveaux motifs d'oxydoréductase | |
WO2018027039A8 (fr) | Compositions et procédés de modulation de la transduction du signal lair | |
WO2018009528A8 (fr) | Immunothérapies anticancéreuses combinées comprenant des agents d'appauvrissement en arginine | |
MX2021006393A (es) | Metodos para expansion ex vivo de celulas exterminadoras naturales y uso de las mismas. | |
CA3010889A1 (fr) | Conservation de cellules nucleees par lyophilisation | |
WO2015128746A3 (fr) | Protéines de fusion tatk-cdkl5, compositions, formulations et utilisation de celles-ci | |
WO2002074345A3 (fr) | Modulation des réponses immunitaires systémiques par transplantation de cellules souches hématopoïétiques transduites avec des gènes codant des antigènes et des molécules de régulation cellulaire présentant des antigènes | |
WO2021076755A8 (fr) | Carte de guide d'activité d'interactions électrophile-cystéine dans des cellules immunitaires humaines primaires | |
WO2020092743A3 (fr) | Méthode de traitement de maladies à l'aide de modulateurs de kinases | |
WO2020223741A3 (fr) | Techniques de neuromodulation pour perturbation de systèmes physiologiques |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20755906 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2021547755 Country of ref document: JP Kind code of ref document: A Ref document number: 3130398 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112021016178 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2020223192 Country of ref document: AU Date of ref document: 20200216 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20217029445 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2020755906 Country of ref document: EP Effective date: 20210915 |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20755906 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 112021016178 Country of ref document: BR Kind code of ref document: A2 Effective date: 20210816 |